CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life.

The company's lead product, PaQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discrete design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections.

CeQur SA was established in January 2008 as a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology. CeQur recently completed a clinical study evaluating PaQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PaQ in 2012.

CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.